Recently, upfront IL-6 blockade mitigated irAE symptoms in a murine model of experimental autoimmune encephalomyelitis while preserving antitumor activity after anti-CTLA-4 exposure (53). The gene discussed is CTLA4; the disease is experimental autoimmune encephalomyelitis.